Advice

following a full submission:

atezolizumab (Tecentriq®) is accepted for use within NHSScotland.

Indication under review: As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥50% tumour cells (TC) or ≥10% tumour-infiltrating immune cells (IC) and who do not have epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC.

In a phase III study, treatment with atezolizumab improved overall survival when compared with chemotherapy in the relevant subgroup of patients with previously untreated metastatic NSCLC (PD-L1 expression ≥50% TC or ≥10% IC).

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2379
Indication:

As monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC.

Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
08 November 2021